ArticleInternational journal of nanomedicine2026
Astragalus Polysaccharide Nanoparticles Alleviate Sepsis-Induced Myocardial Injury by Targeting the HSP90AA1/NLRP3 Signaling Pathway.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate the mechanisms by which Astragalus polysaccharide nanoparticles (APS-CS/TPP) protect against septic myocardial injury, addressing the limited understanding of how APS-CS/TPP specific signaling pathways in this condition. Materials and Methods: Potential targets and pathways of Astragalus polysaccharide (APS) were initially predicted using network pharmacology, molecular docking, and microscale thermophoresis. APS-CS/TPP were prepared using an ion gel method with a chitosan derivative and characterized for formation, size, and surface charge. A murine model of septic myocardial injury was established by cecal ligation and puncture (CLP), and therapeutic outcomes were assessed via echocardiography, ELISA, histology, and Western blot. In vitro, H9c2 cells were stimulated with LPS and treated with APS-CS/TPP, with or without the HSP90AA1 inhibitor TAS-116, followed by evaluation of inflammatory markers and protein expression. Results: APS showed high binding affinity to HSP90AA1. APS-CS/TPP improved survival and attenuated myocardial damage in septic mice. In vitro, they reduced levels of IL-1β, IL-6, and TNF-α, and downregulated HSP90AA1, NLRP3, caspase-1, and IL-1β. These effects were suppressed by TAS-116. Conclusion: APS-CS/TPP protect against septic myocardial injury by inhibiting the HSP90AA1/NLRP3 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.